Cem Akin Selected Research

Tryptases (Tryptase)

1/2022	Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
11/2021	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.
11/2021	Prevalence of mastocytosis and Hymenoptera venom allergy in the United States.
1/2021	Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
1/2020	Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome.
6/2019	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.
1/2019	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
10/2017	Hymenoptera-induced anaphylaxis: is it a mast cell driven hematological disorder?
9/2017	Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis.
5/2017	Tryptase Increase without Mastocytosis or Anaphylaxis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cem Akin Research Topics

Disease

42	Mastocytosis 01/2022 - 01/2002
35	Systemic Mastocytosis 01/2022 - 07/2002
19	Anaphylaxis (Anaphylactic Shock) 01/2022 - 10/2007
11	Hypersensitivity (Allergy) 01/2022 - 05/2015
10	Neoplasms (Cancer) 01/2022 - 03/2002
9	Mast Cell Activation Disorders (Mast-Cell Disease) 01/2022 - 04/2004
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 02/2004
5	Leukemia 06/2015 - 08/2003
4	Mast Cell Activation Syndrome 01/2021 - 05/2015
4	Eosinophilia 09/2011 - 06/2003
3	Hereditary alpha-tryptasemia syndrome 01/2022 - 11/2020
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 10/2014
3	Mast-Cell Leukemia (Leukemia, Mast Cell) 06/2016 - 08/2003
3	Osteoporosis 01/2016 - 01/2002
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2014 - 07/2006
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2007 - 03/2002
3	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2005 - 06/2003
2	COVID-19 01/2022 - 01/2022
2	Inflammation (Inflammations) 11/2020 - 01/2016
2	Blister (Bulla) 01/2019 - 01/2002
2	Sarcoma (Soft Tissue Sarcoma) 06/2015 - 10/2013
2	Pdgfra-Associated Chronic Eosinophilic Leukemia 10/2014 - 04/2012
2	Mast-Cell Sarcoma 04/2013 - 08/2003
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 06/2003
2	Fibrosis (Cirrhosis) 01/2004 - 06/2003
1	Infections 01/2022
1	Communicable Diseases (Infectious Diseases) 10/2021
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2021
1	Diabetes Mellitus 01/2020
1	Lung Diseases (Lung Disease) 01/2020
1	Bites and Stings (Sting) 01/2020
1	Obesity 01/2020
1	Vitamin D Deficiency 06/2019
1	Cutaneous Mastocytosis 01/2019
1	Asthma (Bronchial Asthma) 01/2016
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2014
1	Chronic Urticaria 05/2014
1	Chronic Renal Insufficiency 01/2010
1	Anemia 06/2008
1	Philadelphia Chromosome 06/2008

Drug/Important Bio-Agent (IBA)

22	Tryptases (Tryptase)IBA 01/2022 - 01/2002
11	Immunoglobulin E (IgE)IBA 01/2022 - 01/2010
10	Imatinib Mesylate (Gleevec)FDA Link 04/2013 - 03/2002
8	Biomarkers (Surrogate Marker)IBA 01/2020 - 02/2002
8	Codon (Codons)IBA 06/2019 - 07/2002
7	Arthropod VenomsIBA 01/2022 - 01/2010
4	VaccinesIBA 01/2022 - 01/2019
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2004
4	Stem Cell FactorIBA 04/2012 - 01/2002
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2011 - 01/2004
3	Pharmaceutical PreparationsIBA 01/2022 - 08/2003
3	COVID-19 VaccinesIBA 01/2022 - 10/2021
3	Biological ProductsIBA 01/2022 - 01/2002
3	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 01/2018
3	midostaurinIBA 01/2021 - 06/2016
3	Phosphotransferases (Kinase)IBA 04/2012 - 03/2002
3	Proteins (Proteins, Gene)FDA Link 09/2006 - 02/2004
2	BNT162 VaccineIBA 01/2022 - 01/2022
2	Excipients (Suspending Agents)IBA 01/2022 - 10/2021
2	Genetic Markers (Genetic Marker)IBA 01/2022 - 06/2005
2	Ad26COVS1IBA 01/2022 - 01/2022
2	2019-nCoV Vaccine mRNA-1273IBA 01/2022 - 01/2022
2	Syntex adjuvant formulationIBA 10/2021 - 10/2021
2	AllergensIBA 02/2021 - 10/2019
2	Histamine (Histamine Dihydrochloride)FDA Link 01/2020 - 02/2002
2	Cladribine FDA LinkGeneric 10/2016 - 08/2015
2	Tyrosine (L-Tyrosine)FDA Link 04/2012 - 07/2007
2	Dasatinib (BMS 354825)FDA Link 06/2008 - 07/2006
2	LigandsIBA 07/2006 - 03/2002
2	Interleukin-6 (Interleukin 6)IBA 05/2005 - 01/2002
2	DNA (Deoxyribonucleic Acid)IBA 11/2004 - 07/2002
2	EnzymesIBA 12/2003 - 03/2002
1	avapritinibIBA 01/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 10/2021
1	Polysorbates (PSML)FDA Link 10/2021
1	Blocking AntibodiesIBA 11/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	Interferon-alpha (Interferon Alfa)IBA 10/2016
1	Diphosphonates (Bisphosphonates)IBA 01/2016
1	Clodronic Acid (Clodronate)IBA 01/2016
1	Pamidronate (Aredia)FDA LinkGeneric 01/2016
1	Zoledronic Acid (Zometa)FDA Link 01/2016
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 01/2016
1	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA 11/2014
1	Corticotropin-Releasing HormoneIBA 11/2014
1	Interleukin-5 (Interleukin 5)IBA 04/2012
1	CytokinesIBA 04/2012
1	Lenalidomide (CC 5013)FDA Link 03/2009
1	Erythropoietin FDA Link 06/2008

Therapy/Procedure

24	Therapeutics 01/2022 - 01/2004
4	Hematopoietic Stem Cell Transplantation 01/2017 - 12/2010
3	Drug Therapy (Chemotherapy) 01/2020 - 01/2005
3	Cell Transplantation 01/2018 - 01/2016
2	Precision Medicine 11/2020 - 06/2019
1	Premedication 01/2021
1	Critical Care (Surgical Intensive Care) 01/2019
1	Resuscitation 01/2019
1	Stem Cell Transplantation 06/2015
1	Combination Drug Therapy (Combination Chemotherapy) 12/2010